|Mr. Michael Wolff Jensen||Chairman, Sr. VP & Gen. Counsel||N/A||N/A||1971|
|Mr. Jan Møller Mikkelsen||Pres, CEO, Member of Exec. Board & Exec. Director||N/A||N/A||1960|
|Mr. Scott T. Smith||CFO, Sr. VP & Member of Exec. Board||N/A||N/A||1974|
|Mr. Peter Rasmussen||VP of Fin. & Principal Accounting Officer||N/A||N/A||1969|
|Dr. Harald Rau||Sr. VP & Chief Scientific Officer||N/A||N/A||1970|
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.